Information Provided By: 
Fly News Breaks for March 2, 2018
ZBH
Mar 2, 2018 | 09:18 EDT
After surveying 156 U.S.-based hip and knee surgeons, Stifel analyst Rick Wise said his work suggests surgeons are likely to meaningfully increase Zimmer Biomet utilization when supply returns to full. The responses also strongly point to robust potential adoption of the company's new product pipeline, added Wise, who keeps his Buy rating and $168 price target on the stock.
News For ZBH From the Last 2 Days
There are no results for your query ZBH
